Biotech could see $100B companies; Lab-bred bird flu studies resume;

 @FierceBiotech: Biogen bolsters MS biz with PhIII win for longer-lasting Avonex. News | Follow @FierceBiotech

@JohnCFierce: Flu researchers are getting back to work on controversial genetically engineered viruses, whether U.S. likes it or not. More | Follow @JohnCFierce

@RyanMFierce: Merck CEO pledges to persist with 'good' cholesterol drug program. Story | Follow @RyanMFierce

> Gilead Sciences ($GILD) has started the first of two Phase III clinical trials to evaluate a once-daily, single-tablet medication regimen containing tenofovir alafenamide to treat HIV-1 infection in adults who have not taken HIV drugs. Release

> Studies on the H5N1 avian influenza virus are set to restart after a year-long suspension. Story

> The FDA has approved Novartis ($NVS) drug Exjade (deferasirox) to treat chronic iron overload in patients 10 years of age and older. Release

> X PRIZE Foundation CEO Peter Diamandis thinks biotech is the next industry to see $100 billion companies. Story (sub. req.)

Medical Device News

 @FierceMedDev: FDA slaps Class I tag on Bausch + Lomb's eye surgery recall. Report | Follow @FierceMedDev

 @DamianFierce: Some companies are passing the cost of the device tax down to customers, and hospitals are none too pleased. Story | Follow @DamianFierce

> AngioDynamics spends $15M on microwave ablation tech. Article

> Recall charges drag down Stryker's strong Q4 sales. Story

Pharma News

@FiercePharma: Results from Slovenia's Krka show why pharma's so interested in emerging markets. E. European growth push sales up 6%. More | Follow @FiercePharma

 @AlisonBFierce: After a year-long voluntary moratorium, researchers are set to resume lab-bred bird flu studies. News | Follow @AlisonBFierce

> FDA won't appeal free-speech ruling on off-label marketing. Story

> Lawmakers lash out at Amgen-friendly legislation. Report

Vaccines News

> U.N. excludes vaccine preservative from mercury treaty. More

> Researchers set to resume lab-bred bird flu studies. Report

> Heightened flu season turns focus on vaccine advancements. Story

> Evidence mounts for GSK flu vaccine link to narcolepsy. News

> Novartis lands EU approval of meningitis B vaccine Bexsero. Article

Pharma Manufacturing News

> AmerisourceBergen seeing shifts in drug distribution business. Item

> Drug plants popping up in Kazakhstan. Story

> Counterfeit drug seizures fell significantly in 2012. Report

> Ben Venue consent decree softened to account for drug shortages. News

And Finally... Researchers have discovered an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.